Opendata, web and dolomites


Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography

Total Cost €


EC-Contrib. €






 GLIOMARK project word cloud

Explore the words cloud of the GLIOMARK project. It provides you a very rough idea of what is the project "GLIOMARK" about.

kit    market    greek    validated    photon    global    aggressiveness    innovative    reliability    reconstituted    gliomas    assesses    hence    diagnostic    outcome    instructions    reliably    permeability    approval    tolerated    yield    sme    validate    diagnosis    containing    tomography    reproducibility    accomplished    blood    glioma    ttf    diagnose    detect    unable    diseases    leader    disease    technique    selling    tumor    orphan    gliomark    sale    spect    specificity    latter    safe    computer    subsequent    confirmation    point    pertechnetate    exclusivity    distinguish    preparation    opportunity    barrier    speciality    biomarker    handling    rare    imaging    single    grade    expensive    replace    designation    aggregated    therapies    first    guarantee    magnetic    vivo    proactina    combination    chemical    radiotracer    objective    resonance    diagnostics    gliotect    99mtc    sensitivity    affordable    clinically    fast    exclude    tlr    emission    lifted    niche    grading    hospitals    bbb    mography    prognosis    biopsies    invasive    brain    differential    poor    tetrofosmin   

Project "GLIOMARK" data sheet

The following table provides information about the project.


Organization address
city: BERLIN
postcode: 12207

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website
 Total cost 4˙705˙344 €
 EC max contribution 4˙705˙344 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer To-mography (SPECT). The outcome of GLIOMARK is GlioTect, a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. GlioTect with TTF/SPECT enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies. Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the sale of GlioTect for preparation of TTF for use with SPECT. End users are hospitals that use the kit to reliably diagnose or exclude gliomas without the need for expensive equipment. Taken together, the aggregated unique selling point of SPECT in combination with TTF (generated by means of GlioTect) is the first ever and only glioma diagnostic, which assesses a clinically validated glioma biomarker, has high reliability, reproducibility, sensitivity, as well as specificity, which is used to replace an invasive method, is safe, well tolerated, widely available and more affordable


List of deliverables.
Set up project homepage Websites, patent fillings, videos etc. 2019-07-25 13:49:19

Take a look to the deliverables list in detail:  detailed list of GLIOMARK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOMARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

FURTHER (2019)

Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone Metastasis

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More